This firm's average rating is Strong Buy from 4 analysts. We provide trade recommendations to complement the recent
expert consensus on OptiNose. Our dynamic recommendation engine exercises a multidimensional algorithm to analyze the firm's potential to grow using all technical and fundamental data available at the time.
What is the right price you would pay to acquire a share of OptiNose? For most investors, it would be the price that gives them a wide margin of safety to have minimal downside risk. In other words, most investors are always looking for undervalued stocks. Even if the
future performance is not entirely as expected, the loss of holding it is minimized, and the downside risk is negated. Please read more on our
stock advisor page.
Watch out for price decline
Please consider monitoring OptiNose on a daily basis if you are holding a position in it. OptiNose is trading at a penny-stock level, and the possibility of delisting is much higher compared to other stocks. However, just because the stock is trading under one dollar, does not mean it will be marked for deletion.
Most exchanges require public instruments, such as OptiNose stock to be traded above the $1 level to remain listed. If OptiNose stock price falls below $1 for 30 consecutive trading days, the exchange can delist it. Once the company reaches this point, they will be sent an initial price violation notice directly from an exchange.
What is happening with OptiNose this year
Annual and quarterly reports issued by OptiNose are formal
financial statements that are published yearly and quarterly and sent to OptiNose stockholders. The reports show and break down the current year's ongoing operations and discuss plans for the upcoming year. Annual reports have been a requirement from the
Securities and Exchange Commission (SEC) for businesses owned by the public since 1934.
Companies such as OptiNose often view their annual report as an effective marketing tool to disseminate their perspective on company
future earnings or innovations. With this in mind, many companies devote large sums of money to making their reports attractive and informative. In such instances, the annual report becomes a forum through which a company can communicate to the general public any number of topics that may or may not be directly related to the actual data published in the reports.
OptiNose Gross Profit
OptiNose Gross Profit growth is one of the most critical measures in evaluating the company. The Gross Profit growth rate is calculated simply by comparing OptiNose previous period's values with its current period's values. Each time period you're measuring should be of equal lengths the increase or decrease, in a company's Gross Profit between two periods. Here we show OptiNose Gross Profit growth over the last 10 years. Please check OptiNose's
gross profit and other
fundamental indicators for more details.
Is OptiNose a risky opportunity?
Let's check the volatility. OptiNose is looking slightly risky at this time. Whether you invest your money or manage your clients' funds, remember that it is easy to forget that behind OptiNose (NASDAQ:OPTN) stock is an actual business venture. So, do not let stock picking become an abstract concept by ignoring the elementary risk calculations. picking up a share of an OptiNose stock makes you a part-owner of that company.
OptiNose Current Consensus
Here is the latest trade recommendation based on an ongoing consensus estimate among financial analysis covering OptiNose. The OptiNose consensus assessment is calculated by taking the average estimates from all of the analysts covering OptiNose
| Strong Buy | 4 | 100.0 |
| Buy | 0 | 0.0 |
| Hold | 0 | 0.0 |
| Sell | 0 | 0.0 |
| Strong Sell | 0 | 0.0 |
Are OptiNose technical ratios showing a correction?
OptiNose latest mean deviation surges over 3.36. OptiNose shows above-average downside volatility for the selected time horizon. We advise investors to inspect OptiNose further and ensure that all market timing and asset allocation strategies are consistent with the estimation of OptiNose future alpha.
Our Final Take On OptiNose
Whereas other entities within the drug manufacturers—specialty & generic industry are still a little expensive, even after the recent corrections, OptiNose may offer a potential longer-term growth to institutional investors. To sum up, as of the 27th of December 2020, our present 30 days Buy-Hold-Sell recommendation on the company is
Strong Sell. However, we believe OptiNose is
undervalued with
very high probability of financial unrest for the next two years.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectEditorial Staff
Raphi Shpitalnik is a Junior Member of Macroaxis Editorial Board. Raphael is a young entrepreneur who joined Macroaxis on a part-time basis at the beginning of the pandemic and eventually acquired a real taste for investing and fintech. He likes to analyze different equity instruments across a wide range of industries, focusing primarily on consumer products, sports, fintech, cannabis, and AI.
View Profile This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Macroaxis LLC and Raphi Shpitalnik do not own shares of OptiNose. Please refer to our
Terms of Use for any information regarding our disclosure principles.
Would you like to provide feedback on the content of this article?
You can get in touch with us directly or send us a quick note via email to
editors@macroaxis.com
